Skip to content

瑞雷治疗

US · RLAY #2273 按市值排名 上市于 2020
16.28 -1.02 -5.90%
实时 - 追踪5344个代码 - 心跳于34秒前 · 2026-10-16 20:02

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量减少了1家。
  • 机构持股总比例下降了4.9个百分点。

机构持股

机构持股比例
123.78% -4.86pp
机构数量
308 -1
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund56.07%
VC/PE Fund35.99%
Hedge Fund16.09%
Public Company14.60%
Individual/Insider1.65%
Government Pension Fund0.26%
Sovereign Wealth Fund0.25%
Private Company0.24%
Family Office/Trust0.19%

主要股东 截至 2026-06-30

SB Investment Advisers (UK) Limited 12.73% · 27.90M 股
SoftBank Group Corp. 10.00% · 21.90M 股
FMR 9.70% · 21.27M 股
Casdin Capital, LLC 7.32% · 16.04M 股
BlackRock 6.98% · 15.29M 股
Perceptive Advisors LLC 6.44% · 14.11M 股
Commodore Capital LP 5.48% · 12.00M 股
Vanguard Capital Management, LLC 4.65% · 10.19M 股
State Street Global Advisors 4.62% · 10.13M 股
T. Rowe Price Group, Inc. 4.39% · 9.62M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 17次买入 · 33次卖出

姓名职务持股比例
Sanjiv Patel Chief Executive Officer 0.64%
Mark Murcko Co-Founder 0.45%
Donald Bergstrom President of Research & Development 0.18%
Alexis Borisy Co-Founder & Independent Chairman 0.11%
Brian Adams Chief Legal Officer 0.10%
Peter Rahmer Chief Corporate Development Officer 0.10%
Thomas Catinazzo Chief Financial Officer 0.05%
Douglas Ingram Independent Director 0.01%
SoftBank Group Corp. -- --
Linda Hill Independent Director --

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-07 Donald Bergstrom President of Research & Development Automatic Disposition -8,530 $18.97
2026-09-07 Sanjiv Patel Chief Executive Officer Automatic Disposition -48,199 $18.94
2026-09-07 Thomas Catinazzo Chief Financial Officer Automatic Disposition -17,717 $18.94
2026-08-25 Peter Rahmer Chief Corporate Development Officer Automatic Disposition -4,508 $20.03
2026-08-24 SoftBank Group Corp. -- Private Disposition -6,000,000 $19.40
2026-08-16 Sanjiv Patel Chief Executive Officer Automatic Disposition -48,199 $20.33
2026-08-13 Thomas Catinazzo Chief Financial Officer Automatic Disposition -17,717 $19.74
2026-08-03 Sekar Kathiresan Independent Director Intent to Sell (Form 144) -42,225 $19.57
2026-07-30 Sekar Kathiresan Independent Director Intent to Sell (Form 144) -30,000 $18.79
2026-07-27 Donald Bergstrom President of Research & Development Open Market Disposition -2,237 $18.61
2026-07-27 Peter Rahmer Chief Corporate Development Officer Open Market Disposition -748 $18.61
2026-07-27 Thomas Catinazzo Chief Financial Officer Open Market Disposition -1,459 $18.61
2026-07-20 Sekar Kathiresan Independent Director Intent to Sell (Form 144) -30,000 $19.81
2026-07-19 Sekar Kathiresan Independent Director Intent to Sell (Form 144) -66,055 $19.58
2026-07-06 Sanjiv Patel Chief Executive Officer Automatic Disposition -48,199 $19.58
2026-07-05 Donald Bergstrom President of Research & Development Automatic Disposition -8,660 $18.71
2026-07-05 Thomas Catinazzo Chief Financial Officer Automatic Disposition -17,717 $18.69
2026-06-29 Peter Rahmer Chief Corporate Development Officer Other Acquisition +3,056 $6.95
2026-06-29 Peter Rahmer Chief Corporate Development Officer Automatic Disposition -50,000 $19.09
2026-06-29 Sanjiv Patel Chief Executive Officer Other Acquisition +3,056 $6.95

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:02:11 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

瑞雷治疗 讨论区 0 条评论

发表评论